Study backs tamoxifen for young womenBMJ 1998; 316 doi: https://doi.org/10.1136/bmj.316.7144.1553h (Published 23 May 1998) Cite this as: BMJ 1998;316:1553
- Hilary Bower
Results from the largest ever collection of randomised data on a cancer drug suggest tamoxifen should be given to all patients with breast cancer who have had surgery for hormone dependent tumours, regardless of age.
The new data decisively overturns accepted wisdom that tamoxifen has no benefit for younger women or those with breast only tumours. It also indicates that the drug has a substantial benefit on top of chemotherapy. Coordinators of the Early Breast Cancer Trialists' Collaborative Group based at Oxford University's Clinical Trial Service Unit say that acting on these results will prevent around 20000 more deaths from breast cancer a year worldwide, including …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial